Role of positron emission tomography in thyroid and neuroendocrine tumours

Giorgio Treglia, Alexander S Kroiss, Arnoldo Piccardo, Filippo Lococo, Prasanna Santhanam, Alessio Imperiale

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND: Positron emission tomography (PET) is an established imaging method in oncology. PET/computed tomography (PET/CT) and PET/magnetic resonance imaging (PET/MRI) are hybrid techniques which combine morphological information obtained by CT and MRI with functional data provided by PET. Several radiotracers evaluating different metabolic pathways or receptor status can be used as PET radiotracers to assess endocrine tumours such as thyroid tumours or neuroendocrine neoplasms (NENs). This review is focused to describe the role of PET imaging using different radiotracers in patients with thyroid tumours and NENs.

METHODS: The role of PET imaging with different radiotracers in several endocrine tumours including thyroid tumours, gastroenteropancreatic neoplasms (GEP-NENs), lung neuroendocrine neoplasms (LNENs), pheochromocytomas (PCC) and paragangliomas (PGL), and multiple endocrine neoplasia (MEN) syndromes has been described.

RESULTS: Fluorine-18 fluorodeoxyglucose (18F-FDG) PET evaluating the glucose metabolism provides useful diagnostic and prognostic information in patients with thyroid tumours. Iodine-124 (124I) assessing the iodine metabolism (124I) PET may be used for dosimetry and diagnostic purposes in thyroid tumours. In patients with NENs specific radiotracers can be used for diagnostic purposes such as somatostatin analogues labeled with gallium-68 (68Ga-DOTA-peptides) evaluating somatostatin receptor expression and fluorine-18 fluorodihydroxyphenylalanine (18F- FDOPA) assessing the uptake, decarboxylation and storage of amine precursors. One advantage of 68Ga-DOTA-peptides PET is to select patients with well-differentiated and inoperable NENs for peptide receptor radionuclide therapy (PRRT). 18F-FDG PET may provide useful prognostic information in patients with high-grade NENs.

CONCLUSIONS: PET imaging with different radiotracers is a useful functional imaging technique in the work-up of several endocrine tumours.

Original languageEnglish
JournalMinerva Endocrinologica
DOIs
Publication statusE-pub ahead of print - Sep 25 2017

Fingerprint

Neuroendocrine Tumors
Positron-Emission Tomography
Thyroid Gland
Neoplasms
Fluorodeoxyglucose F18
Iodine
Magnetic Resonance Imaging
Multiple Endocrine Neoplasia
Paraganglioma
Somatostatin Receptors
Peptides
Gallium
Decarboxylation
Peptide Receptors
Fluorine
Pheochromocytoma
Metabolic Networks and Pathways
Somatostatin
Radioisotopes
Amines

Keywords

  • Journal Article

Cite this

Role of positron emission tomography in thyroid and neuroendocrine tumours. / Treglia, Giorgio; Kroiss, Alexander S; Piccardo, Arnoldo; Lococo, Filippo; Santhanam, Prasanna; Imperiale, Alessio.

In: Minerva Endocrinologica, 25.09.2017.

Research output: Contribution to journalArticle

Treglia, Giorgio ; Kroiss, Alexander S ; Piccardo, Arnoldo ; Lococo, Filippo ; Santhanam, Prasanna ; Imperiale, Alessio. / Role of positron emission tomography in thyroid and neuroendocrine tumours. In: Minerva Endocrinologica. 2017.
@article{bdc541d1e2ad434f9dbdcf86a28e8f5f,
title = "Role of positron emission tomography in thyroid and neuroendocrine tumours",
abstract = "BACKGROUND: Positron emission tomography (PET) is an established imaging method in oncology. PET/computed tomography (PET/CT) and PET/magnetic resonance imaging (PET/MRI) are hybrid techniques which combine morphological information obtained by CT and MRI with functional data provided by PET. Several radiotracers evaluating different metabolic pathways or receptor status can be used as PET radiotracers to assess endocrine tumours such as thyroid tumours or neuroendocrine neoplasms (NENs). This review is focused to describe the role of PET imaging using different radiotracers in patients with thyroid tumours and NENs.METHODS: The role of PET imaging with different radiotracers in several endocrine tumours including thyroid tumours, gastroenteropancreatic neoplasms (GEP-NENs), lung neuroendocrine neoplasms (LNENs), pheochromocytomas (PCC) and paragangliomas (PGL), and multiple endocrine neoplasia (MEN) syndromes has been described.RESULTS: Fluorine-18 fluorodeoxyglucose (18F-FDG) PET evaluating the glucose metabolism provides useful diagnostic and prognostic information in patients with thyroid tumours. Iodine-124 (124I) assessing the iodine metabolism (124I) PET may be used for dosimetry and diagnostic purposes in thyroid tumours. In patients with NENs specific radiotracers can be used for diagnostic purposes such as somatostatin analogues labeled with gallium-68 (68Ga-DOTA-peptides) evaluating somatostatin receptor expression and fluorine-18 fluorodihydroxyphenylalanine (18F- FDOPA) assessing the uptake, decarboxylation and storage of amine precursors. One advantage of 68Ga-DOTA-peptides PET is to select patients with well-differentiated and inoperable NENs for peptide receptor radionuclide therapy (PRRT). 18F-FDG PET may provide useful prognostic information in patients with high-grade NENs.CONCLUSIONS: PET imaging with different radiotracers is a useful functional imaging technique in the work-up of several endocrine tumours.",
keywords = "Journal Article",
author = "Giorgio Treglia and Kroiss, {Alexander S} and Arnoldo Piccardo and Filippo Lococo and Prasanna Santhanam and Alessio Imperiale",
year = "2017",
month = "9",
day = "25",
doi = "10.23736/S0391-1977.17.02742-0",
language = "English",
journal = "Minerva Endocrinologica",
issn = "0391-1977",
publisher = "Edizioni Minerva Medica S.p.A.",

}

TY - JOUR

T1 - Role of positron emission tomography in thyroid and neuroendocrine tumours

AU - Treglia, Giorgio

AU - Kroiss, Alexander S

AU - Piccardo, Arnoldo

AU - Lococo, Filippo

AU - Santhanam, Prasanna

AU - Imperiale, Alessio

PY - 2017/9/25

Y1 - 2017/9/25

N2 - BACKGROUND: Positron emission tomography (PET) is an established imaging method in oncology. PET/computed tomography (PET/CT) and PET/magnetic resonance imaging (PET/MRI) are hybrid techniques which combine morphological information obtained by CT and MRI with functional data provided by PET. Several radiotracers evaluating different metabolic pathways or receptor status can be used as PET radiotracers to assess endocrine tumours such as thyroid tumours or neuroendocrine neoplasms (NENs). This review is focused to describe the role of PET imaging using different radiotracers in patients with thyroid tumours and NENs.METHODS: The role of PET imaging with different radiotracers in several endocrine tumours including thyroid tumours, gastroenteropancreatic neoplasms (GEP-NENs), lung neuroendocrine neoplasms (LNENs), pheochromocytomas (PCC) and paragangliomas (PGL), and multiple endocrine neoplasia (MEN) syndromes has been described.RESULTS: Fluorine-18 fluorodeoxyglucose (18F-FDG) PET evaluating the glucose metabolism provides useful diagnostic and prognostic information in patients with thyroid tumours. Iodine-124 (124I) assessing the iodine metabolism (124I) PET may be used for dosimetry and diagnostic purposes in thyroid tumours. In patients with NENs specific radiotracers can be used for diagnostic purposes such as somatostatin analogues labeled with gallium-68 (68Ga-DOTA-peptides) evaluating somatostatin receptor expression and fluorine-18 fluorodihydroxyphenylalanine (18F- FDOPA) assessing the uptake, decarboxylation and storage of amine precursors. One advantage of 68Ga-DOTA-peptides PET is to select patients with well-differentiated and inoperable NENs for peptide receptor radionuclide therapy (PRRT). 18F-FDG PET may provide useful prognostic information in patients with high-grade NENs.CONCLUSIONS: PET imaging with different radiotracers is a useful functional imaging technique in the work-up of several endocrine tumours.

AB - BACKGROUND: Positron emission tomography (PET) is an established imaging method in oncology. PET/computed tomography (PET/CT) and PET/magnetic resonance imaging (PET/MRI) are hybrid techniques which combine morphological information obtained by CT and MRI with functional data provided by PET. Several radiotracers evaluating different metabolic pathways or receptor status can be used as PET radiotracers to assess endocrine tumours such as thyroid tumours or neuroendocrine neoplasms (NENs). This review is focused to describe the role of PET imaging using different radiotracers in patients with thyroid tumours and NENs.METHODS: The role of PET imaging with different radiotracers in several endocrine tumours including thyroid tumours, gastroenteropancreatic neoplasms (GEP-NENs), lung neuroendocrine neoplasms (LNENs), pheochromocytomas (PCC) and paragangliomas (PGL), and multiple endocrine neoplasia (MEN) syndromes has been described.RESULTS: Fluorine-18 fluorodeoxyglucose (18F-FDG) PET evaluating the glucose metabolism provides useful diagnostic and prognostic information in patients with thyroid tumours. Iodine-124 (124I) assessing the iodine metabolism (124I) PET may be used for dosimetry and diagnostic purposes in thyroid tumours. In patients with NENs specific radiotracers can be used for diagnostic purposes such as somatostatin analogues labeled with gallium-68 (68Ga-DOTA-peptides) evaluating somatostatin receptor expression and fluorine-18 fluorodihydroxyphenylalanine (18F- FDOPA) assessing the uptake, decarboxylation and storage of amine precursors. One advantage of 68Ga-DOTA-peptides PET is to select patients with well-differentiated and inoperable NENs for peptide receptor radionuclide therapy (PRRT). 18F-FDG PET may provide useful prognostic information in patients with high-grade NENs.CONCLUSIONS: PET imaging with different radiotracers is a useful functional imaging technique in the work-up of several endocrine tumours.

KW - Journal Article

U2 - 10.23736/S0391-1977.17.02742-0

DO - 10.23736/S0391-1977.17.02742-0

M3 - Article

C2 - 28949122

JO - Minerva Endocrinologica

JF - Minerva Endocrinologica

SN - 0391-1977

ER -